REVOLUTIONARY INNOVATION

Plant Extracellular Vesicle-Mediated Therapeutic Phospholipid Platform for Membrane Repair in Inflammatory Bowel Disease

A Novel Membrane Therapeutics Approach

Principal Investigator:	Dr. María Beatriz Herrera Sánchez, PhD
Institution:	ExoVitae Lab, University of Turin
Innovation Type:	Membrane Therapeutics Platform Patent
Technology Readiness:	TRL 2 (Technology Concept Formulated)
Market Potential:	$27B IBD + $15B Membrane Therapeutics
Patent Strategy:	Composition + Method + Use Claims
Funding Target:	SBIR Phase I ($500K) + Phase II ($2M)

Paradigm Shift: From Drug Delivery to Membrane Therapeutics

- **Novel mechanism:** Direct membrane repair vs. drug delivery approaches
- **Clear IP position:** Distinct from all existing CsA-prodrug and plant EV prior art
- **Platform technology:** Therapeutic phospholipids for multiple inflammatory diseases
- **Natural approach:** Food-derived EVs with engineered therapeutic lipid compositions

Critical Differentiation:

This innovation is specifically distinct from technical and IP limitations in existing approaches:

- **NOT** CsA-phospholipid prodrugs (extensively covered by Dahan et al.)
- **NOT** PLGA-based drug delivery (incompatible with phospholipid requirements)
- **NOT** standard plant EV drug carriers (focuses on membrane composition modification)

Prepared by: ExoVitae Research Team
University of Turin, Italy

November 23, 2025

Contents

1 Executive Summary

This proposal presents a revolutionary membrane therapeutics platform that addresses inflammatory bowel disease (IBD) through direct membrane repair rather than conventional drug delivery approaches. Our innovation combines plant-derived extracellular vesicles (EVs) with engineered therapeutic phospholipid compositions to restore intestinal barrier function and modulate inflammatory membrane dynamics.

1.1 Innovation Breakthrough

Unlike existing approaches that focus on drug delivery or single-mechanism targeting, our platform delivers **therapeutic glycerophospholipid compositions** that directly integrate with and repair damaged cellular membranes in IBD tissues. This represents a fundamental paradigm shift from treating symptoms to addressing the root membrane pathology underlying inflammatory diseases.

Key Innovation Elements:

- **Membrane therapeutics:** Direct phospholipid-mediated membrane repair and barrier restoration
- **Engineered plant EVs:** Natural carriers optimized for therapeutic lipid delivery and integration
- **Multi-lipid platform:** Specialized phospholipid compositions targeting different aspects of membrane dysfunction
- **Food-derived approach:** Scalable production from citrus and ginger processing waste streams

1.2 Competitive Positioning and IP Strategy

Our approach is carefully distinct from existing intellectual property while creating strong novel patent positions:

Clear Differentiation from Prior Art:

- **vs. CsA-prodrug approaches:** Focus on membrane repair through true phospholipids rather than drug prodrug delivery
- **vs. existing plant EV work:** Engineered therapeutic phospholipid compositions (15–60 mol% enrichment) rather than natural cargo alone
- **vs. polymeric drug carriers: Exclusively true glycerophospholipids** (no polymeric cores, no phospholipid-drug prodrugs): all therapeutic effect arises from native-like phospholipids integrated in plant EV membranes

Our invention is deliberately distinct from:

- CsA-phospholipid prodrug and related drug-phospholipid conjugate prior art
- Polymeric nanocarrier systems (PLGA, PLA, PCL, etc.)
- Synthetic liposome platforms without natural EV tropism
- Standard phosphatidylcholine supplements (LT-02 and related products)

Novel Patent Positions:

- **Composition of matter:** Therapeutic glycerophospholipid-enriched plant EVs with quantified enrichment
- **Manufacturing methods:** EV-phospholipid integration technologies and metabolic engineering
- **Medical use:** IBD treatment through membrane composition modulation and barrier restoration

1.3 Market Opportunity

The confluence of IBD therapeutics ($27B market) and emerging membrane therapeutics represents a compelling commercial opportunity. Our platform addresses critical unmet needs in IBD treatment while establishing a foundation technology for multiple inflammatory conditions.

Commercial Advantages:

- Natural, food-derived approach with established regulatory precedent
- Platform extensibility to multiple inflammatory diseases
- Scalable manufacturing leveraging existing food industry infrastructure
- Superior safety profile compared to systemic immunosuppressive approaches

2 Technical Innovation: Membrane Therapeutics Platform

2.1 Definition of Therapeutic Phospholipids

Therapeutic glycerophospholipids in this invention are *non-conjugated, "true" glycerophospholipids* – molecules with a glycerol backbone, a phosphate-containing polar headgroup (e.g., choline, serine, ethanolamine, inositol), and two fatty-acyl chains, which may be naturally occurring or synthetically defined, and are **not covalently linked to non-lipid drugs** (i.e., not phospholipid prodrugs).

The therapeutic effect arises from:

- **Membrane composition modulation:** Restoring optimal phospholipid ratios and molecular species in diseased tissue
- **Acyl chain engineering:** Enrichment in specific fatty acids (omega-3 PUFA, optimal chain length/saturation) that enhance barrier function and resolve inflammation
- **Headgroup selection:** Defined PC/PE/PS compositions that restore membrane biophysical properties

This platform uses **exclusively true glycerophospholipids** (no polymeric cores, no phospholipid-drug prodrugs): all therapeutic effects arise from native-like phospholipids integrated in plant EV membranes.

2.2 Scientific Rationale

2.2.1 IBD Membrane Pathology: Quantitative Defects

Inflammatory bowel disease is fundamentally characterized by specific, quantifiable membrane alterations:

Documented Lipid Dysregulation in IBD:

- **Increased LPC/PC ratio:** UC mucosa shows LPC/PC > 0.30 vs. healthy < 0.15 (Boldyreva et al., IJMS 2021)
- **Decreased omega-3 index:** Reduced EPA+DHA in mucosal phospholipids ($<8\%$ vs. healthy $>12\%$)
- **Altered PC/PE ratio:** Shift from optimal 2.0–2.5 to >3.0 or <1.5 in inflamed tissue
- **Increased arachidonic acid:** Elevated 20:4(n-6) content (>25 mol%) driving pro-inflammatory eicosanoid production
- **Reduced linoleic/-linolenic:** Decreased 18:2 and 18:3 fatty acids essential for barrier integrity

Functional Consequences:

- **Intestinal barrier dysfunction:** Loss of tight junction integrity, increased permeability (TEER $<50\%$ of healthy)
- **Inflammatory membrane signaling:** Altered lipid raft organization favoring pro-inflammatory pathways
- **Impaired membrane repair:** Deficient mechanisms for restoring barrier function after inflammatory damage

Current treatments focus on immune suppression or anti-inflammatory approaches but **fail to address the underlying membrane defects** that perpetuate disease progression.

2.2.2 Membrane Therapeutics Approach: Targeted Correction

Our platform directly targets membrane pathology through **quantitatively defined phospholipid replacement therapy**:

Therapeutic Phospholipid Compositions (Flagship Examples):

1. **Barrier-Repair Mix (BRM):**
    - 30–40 mol% PC with linoleic acid (18:2) enrichment
    - 15–20 mol% PS with DHA/EPA (omega-3) at sn-2 position
    - 10–15 mol% PE with defined unsaturation (18:1, 18:2)
    - 5–10 mol% cholesterol for membrane stabilization
    - Target: LPC/PC ratio < 0.15, PC/PE ratio 2.0–2.5
    - **Rationale:** Restores mucus/epithelial PC content, stabilizes tight junctions, reduces permeability
2. **Resolution-Promoting Mix (RPM):**
    - 25–35 mol% DHA-PC (precursor to resolvins, protectins, maresins)
    - 15–20 mol% EPA-PE (precursor to specialized pro-resolving mediators)
    - Reduced arachidonic acid content ($<$10 mol% vs. $>$25% in IBD)
    - Enriched 18:3 (-linolenic acid) for anti-inflammatory signaling
    - Target: Omega-3 index $>$15%, AA/EPA ratio $<$3
    - **Rationale:** Shifts membrane toward pro-resolution lipid mediator generation, dampens inflammatory raft signaling

All components: Non-conjugated, true glycerophospholipids with no covalent drug attachments.

2.3 Platform Architecture

2.3.1 Plant EV Carrier System

Source Selection: Multi-plant approach leveraging complementary properties

- ***Citrus limon*:** Natural anti-inflammatory compounds (hesperidin, naringenin) and proven gut tropism
- ***Zingiber officinale*:** Established IBD efficacy (gingerols, shogaols) and membrane-active constituents
- ***Brassica oleracea*:** High native phospholipid content and barrier-protective glucosinolates

EV Engineering: Advanced modifications for therapeutic phospholipid delivery

- **Metabolic engineering** of plant sources for enhanced therapeutic lipid content (omega-3 enriched growth media)
- **Post-isolation membrane enrichment** with specific phospholipid compositions via fusion/co-incubation
- **Surface modifications** to enhance membrane fusion and integration with intestinal epithelium

2.3.2 Differentiation from LT-02 and PC Products

LT-02 (Delayed-Release Phosphatidylcholine):

- Mechanism: Topical luminal supplementation
- Delivery: PC released in colon, enriches mucus surface layer
- Limitation: Limited cellular uptake; primarily mucus-level effect
- Result: Partial barrier restoration but minimal impact on epithelial/immune cell membrane composition

Our PDEV-Therapeutic Phospholipid Platform:

- Mechanism: Direct cellular membrane integration
- Delivery: EVs fuse/endocytose into epithelial cells and immune cells
- Advantage: Delivers phospholipids to **plasma membrane, organelles, and intracellular compartments**
- Result: Multi-lipid compositions (not just PC) restore comprehensive membrane properties
- Synergy: Co-delivery of natural bioactive plant compounds that enhance membrane repair

Key Distinction: We deliver **defined, multi-component phospholipid mixtures** directly into cellular membranes via EV fusion, not just PC supplementation at the mucosal surface.

3 Intellectual Property Strategy

3.1 Patent Portfolio Architecture

3.1.1 Patent 1: Composition of Matter

Title: "Therapeutic Glycerophospholipid-Enriched Plant Extracellular Vesicles for Membrane Repair"

Independent Claim 1: A pharmaceutical composition comprising:

(a) plant-derived extracellular vesicles isolated from edible plant sources selected from *Citrus* species, *Zingiber officinale*, and *Brassica oleracea*; and

(b) one or more **therapeutic glycerophospholipids** integrated within the membrane structure of said extracellular vesicles,

wherein said therapeutic glycerophospholipids are **non-conjugated, non-prodrug phospholipids** having:

- a glycerol backbone,
- a phosphate-containing polar headgroup selected from phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, and related glycerophospholipid analogs, and
- two fatty-acyl chains, which may be naturally occurring or synthetically defined,

and wherein said therapeutic glycerophospholipids are:

- present at 15–60 mol% of total vesicle membrane phospholipids, and
- enriched at least 1.5-fold relative to unmodified plant extracellular vesicles from the same source,

and wherein the composition is formulated for treatment of inflammatory bowel disease through direct membrane integration and repair.

Dependent Claims (Examples):

Claim 2. The composition of Claim 1, wherein the therapeutic glycerophospholipids comprise:

- 30–40 mol% phosphatidylcholine enriched in linoleic acid (18:2),
- 15–20 mol% phosphatidylserine with omega-3 fatty acids (EPA, DHA),
- and wherein the composition exhibits an LPC/PC ratio < 0.20 and PC/PE ratio of 2.0–2.5.

Claim 3. The composition of Claim 1, wherein the therapeutic glycerophospholipids comprise:

- 25–35 mol% DHA-containing phosphatidylcholine,
- 15–20 mol% EPA-containing phosphatidylethanolamine,
- and wherein the composition exhibits an omega-3 index $> 15\%$ and arachidonic acid/EPA ratio < 3.

Claim 4. The composition of Claim 1, consisting essentially of therapeutic glycerophospholipids and native plant EV membrane lipids, wherein no polymeric nanoparticle cores or phospholipid-drug conjugates are present.

Claim 5. The composition of Claim 1, wherein the plant-derived extracellular vesicles exhibit stability in simulated gastric fluid (pH 1.2) for at least 2 hours with $> 80\%$ retention of therapeutic glycerophospholipid content.

3.1.2 Patent 2: Manufacturing Methods

Title: "Methods for Producing Therapeutic Glycerophospholipid-Integrated Plant Extracellular Vesicles"

Independent Claim 1: A method for producing therapeutic extracellular vesicle compositions comprising:

(i) isolating extracellular vesicles from plant sources selected from *Citrus* species, *Zingiber officinale*, and *Brassica oleracea* by differential centrifugation and size-exclusion chromatography;

(ii) preparing therapeutic glycerophospholipid compositions comprising non-conjugated membrane-repair and anti-inflammatory lipids;

(iii) integrating said therapeutic glycerophospholipid compositions into the membrane structure of said extracellular vesicles through membrane fusion techniques; and

(iv) characterizing the resulting compositions for therapeutic glycerophospholipid content, enrichment relative to native EVs, and membrane integration efficiency by lipidomic analysis,

thereby producing plant extracellular vesicles with enhanced therapeutic membrane-modifying properties.

Dependent Claim: The method of Claim 1, wherein step (i) further comprises metabolic engineering of plant sources via omega-3 enriched growth conditions prior to EV isolation.

3.1.3 Patent 3: Medical Use Claims

Title: "Treatment of Inflammatory Bowel Disease Through Membrane Composition Modulation"

Independent Claim 1: A method of treating inflammatory bowel disease in a patient in need thereof, comprising orally administering a therapeutically effective amount of therapeutic glycerophospholipid-enriched plant extracellular vesicles as defined in Patent 1, Claim 1,

wherein said administration results in:

(a) integration of non-conjugated therapeutic glycerophospholipids into intestinal epithelial cell membranes;

(b) restoration of intestinal barrier function through membrane composition modulation; and

(c) reduction of inflammatory membrane pathology associated with inflammatory bowel disease.

3.2 IP Landscape Positioning

Clear Differentiation Points:

- **Mechanism:** Membrane therapeutics vs. drug delivery approaches

- **Components:** Non-conjugated therapeutic glycerophospholipids vs. prodrug conjugates
- **Integration:** Direct membrane fusion vs. enzymatic activation
- **Platform:** Multi-lipid compositions vs. single drug entities
- **Chemistry:** True phospholipids only (no polymeric cores, no drug-lipid conjugates)

Defensive Strategy:

- Broad platform claims to protect core technology
- Specific manufacturing know-how as trade secrets
- Continuation and divisional applications for ongoing protection
- International filing strategy in key markets (US, EU, Japan, China)

4 SBIR Phase I Research Proposal

4.1 Project Title

Plant Extracellular Vesicle-Mediated Therapeutic Phospholipid Platform for Membrane Repair in Inflammatory Bowel Disease

4.2 Project Summary

Inflammatory bowel disease (IBD) affects over 3 million Americans and is characterized by chronic inflammation and intestinal barrier dysfunction with specific, quantifiable membrane lipid abnormalities. Current treatments focus on immune suppression but fail to address the underlying membrane pathology that perpetuates disease progression. This proposal presents a revolutionary membrane therapeutics approach using plant-derived extracellular vesicles (EVs) engineered with therapeutic glycerophospholipid compositions to directly repair damaged intestinal membranes and restore barrier function.

4.3 Specific Aims

4.3.1 Specific Aim 1: Develop and Characterize Therapeutic Glycerophospholipid-Enriched Plant EV Platform

Rationale: Establish robust methods for producing plant EVs with defined therapeutic glycerophospholipid compositions optimized for membrane repair and barrier restoration.

Approach:

Platform constraint: All formulations will be built **exclusively from true glycerophospholipids and plant EV lipids**; no polymeric nanoparticle cores or phospholipid-drug prodrugs will be used in this platform.

We will isolate EVs from three complementary plant sources: *Citrus limon* (anti-inflammatory properties), *Zingiber officinale* (proven IBD efficacy), and *Brassica oleracea* (membrane-protective compounds). Therapeutic glycerophospholipid compositions will be designed based on membrane repair requirements and integrated into plant EVs using novel membrane fusion techniques.

Therapeutic Glycerophospholipid Compositions:

1. **Barrier-Repair Mix (BRM):**
    - 30–40 mol% PC with linoleic acid (18:2) enrichment
    - 15–20 mol% omega-3 PS (DHA/EPA at sn-2)
    - 10–15 mol% PE with 18:1, 18:2
    - Target: LPC/PC ratio < 0.15, PC/PE ratio 2.0–2.5
2. **Resolution-Promoting Mix (RPM):**
    - 25–35 mol% DHA-PC (resolvins/protectins precursor)

- 15–20 mol% EPA-PE (SPM precursor)
- Reduced arachidonic acid ($<$10 mol%)
- Target: Omega-3 index $>$ 15%, AA/EPA ratio $<$ 3

3. **All components:** Non-conjugated, true glycerophospholipids

Characterization:

- Size distribution (DLS, NTA)
- Morphology (TEM)
- **Lipidomic profiling** (LC-MS/MS quantifying PC/PE/PS mol%, fatty acid composition, LPC/PC ratio, omega-3 index, PC/PE ratio)
- Stability assessment (4°C, -20°C, -80°C over 4 weeks)
- GI stability (simulated gastric fluid pH 1.2, 2h; simulated intestinal fluid pH 6.8, 6h)

Milestones:

- Reproducible isolation of plant EVs with $>10^{12}$ particles/mL concentration
- Successful integration of therapeutic glycerophospholipids at 15–30 mol% of total membrane lipids
- **Achieve predefined therapeutic lipid profiles:**
  - BRM: PC/PE ratio 2.0–2.5 $\pm$ 0.3, LPC/PC $<$ 0.20
  - RPM: Omega-3 index $>$ 15%, AA/EPA ratio $<$ 3.5
- **Demonstrate $\geq$1.5-fold enrichment in therapeutic lipids vs. unmodified EVs from the same source** (across $\geq$3 independent batches)
- Demonstrated stability for $>$4 weeks at 4°C with $<$10% lipid degradation

Go/No-Go (Month 4): Achieve all metrics across 3 independent batches for at least 2 plant sources and 1 therapeutic mix.

4.3.2 Specific Aim 2: Demonstrate Membrane Integration and Therapeutic Activity

Rationale: Validate that therapeutic glycerophospholipid-enriched plant EVs can integrate with intestinal epithelial membranes and restore barrier function in IBD-relevant models.

Approach:

We will test membrane integration using fluorescently-labeled **non-conjugated therapeutic glycerophospholipids** and assess barrier function restoration in intestinal epithelial cell models (Caco-2, organoids) and ex vivo intestinal tissue preparations.

Demonstration that non-conjugated therapeutic glycerophospholipids delivered in plant EV membranes stably integrate into epithelial membranes and restore barrier function will be assessed through:

- **Membrane integration:**
  - Confocal microscopy tracking fluorescent lipid incorporation into plasma membrane and organelles
  - Lipidomic analysis of treated cells (LC-MS/MS) confirming therapeutic lipid uptake
  - Time-course studies (0, 1, 3, 6, 24, 48h) measuring integration efficiency
  - Target: $>50\%$ of cells show membrane integration within 6h
- **Barrier function restoration (baseline conditions):**
  - Trans-epithelial electrical resistance (TEER) measurements
  - Permeability assays (FITC-dextran 4 kDa flux)
  - Tight junction protein expression (ZO-1, occludin, claudins) by Western blot and immunofluorescence
  - Target: Restore TEER to $>80\%$ of healthy control levels
- **Inflammatory challenge model:**
  - TNF-α (10 ng/mL) + IFN-γ (20 ng/mL) stimulation of monolayers
  - LPS-challenged ex vivo colon explants
  - Assessment: Barrier protection vs. inflammatory damage
  - Target: Maintain TEER $>60\%$ vs. pre-challenge baseline (vs. $<40\%$ in untreated challenged cells)
- **Inflammatory marker assessment:**
  - Cytokine quantification (IL-6, IL-8, TNF-α) by ELISA
  - Pro-resolving lipid mediator generation (resolvins, protectins) by LC-MS/MS
  - Target: $\geq 50\%$ reduction in inflammatory markers vs. challenged controls

Milestones:

- Demonstrated membrane integration with $>50\%$ efficiency in epithelial cell models
- Restoration of barrier function to $>80\%$ of healthy control levels (baseline conditions)
- Protection of barrier function to $>60\%$ of baseline under inflammatory challenge
- Significant reduction ($\geq 50\%$) in inflammatory markers compared to untreated controls
- Increased pro-resolving mediator generation ($\geq$2-fold) with RPM formulation

Go/No-Go (Month 8): Membrane integration confirmed in ≥ 2 models; barrier restoration to $>70\%$ of healthy control; inflammatory protection demonstrated.

4.3.3 Specific Aim 3: Validate Therapeutic Efficacy in Preclinical IBD Models

Rationale: Demonstrate therapeutic potential and safety of the membrane therapeutics platform in relevant animal models of IBD.

Approach:

Using DSS-induced colitis in C57BL/6 mice (n=10/group), we will compare oral administration of:

1. Vehicle control (PBS)
2. Standard plant EVs (unmodified)
3. Therapeutic glycerophospholipid-enriched plant EVs (BRM)
4. Therapeutic glycerophospholipid-enriched plant EVs (RPM)
5. Conventional IBD treatment (5-ASA or corticosteroids) for comparison
6. **Optional: Delayed-release PC (LT-02-like) for direct comparison to existing PC therapy**

Endpoints:

Efficacy:

- Daily disease activity index (DAI): weight loss, stool consistency, fecal blood
- Terminal (Day 8): colon length, histopathological assessment (blinded scoring)
- **Barrier function markers:** Mucosal permeability (FITC-dextran gavage), tight junction proteins, epithelial integrity
- Inflammatory markers: Tissue cytokines (IL-1β, TNF-α, IL-6), MPO activity
- **Lipidomic analysis of colonic tissue:** Confirm therapeutic lipid integration and membrane composition normalization

Biodistribution and Safety:

- Fluorescently labeled EVs: Track distribution to intestinal tissues
- Tissue phospholipid content: Quantify therapeutic lipid levels in colon, kidney, liver, spleen
- Safety evaluation: Body weight, organ weights, histology of major organs, serum chemistry

Milestones:

- Significant improvement in disease activity scores vs. vehicle control ($\geq$40% reduction in DAI)
- Histological evidence of membrane repair and barrier restoration (histology score $\geq$50% improvement)
- **Mucosal lipid composition normalization:** LPC/PC ratio restored toward healthy levels ($<$0.20), omega-3 index increased ($>$12%)
- Demonstration of safety with no adverse effects at therapeutic doses

- **Superior or non-inferior efficacy vs. LT-02-like PC control** (if tested)

Go/No-Go (Month 12): Meet efficacy criteria (DAI reduction $\geq$40%, histology improvement $\geq$50%); demonstrate safety; confirm membrane lipid normalization in colonic tissue.

5 Commercial Viability and Market Analysis

5.1 Market Opportunity Assessment

5.1.1 Primary Target Market: IBD Therapeutics

Market Size and Growth:

- Global IBD therapeutics market: $27.4 billion (2024)
- Projected growth to $39.1 billion by 2030 (CAGR: 6.1%)
- US market represents 40% of global opportunity ($11B annually)

Patient Population:

- 3.1 million IBD patients in the United States
- 6–8 million patients globally with increasing incidence rates
- 30% of patients inadequately controlled with current therapies

Unmet Medical Needs:

- Limited efficacy of current treatments in achieving barrier repair
- Significant adverse effects from systemic immunosuppressive approaches
- High treatment costs ($50–70K annually for biologics) and frequent hospitalizations
- Lack of therapies addressing underlying membrane pathology

5.2 Competitive Positioning

5.2.1 Current IBD Treatment Landscape

Standard of Care Limitations:

- **Aminosalicylates:** Limited to mild disease, poor barrier repair
- **Corticosteroids:** Significant side effects, temporary symptom relief
- **Immunomodulators:** Systemic toxicity, increased infection risk
- **Biologics:** High cost ($50–70K annually), limited barrier restoration
- **PC products (LT-02):** Topical mucus-level effect, limited cellular uptake

Our Competitive Advantages:

- **Direct membrane repair mechanism** addressing root pathology (not just symptom management)
- **Multi-component therapeutic lipid delivery** (vs. PC-only supplementation)
- Natural, food-derived approach with superior safety profile

- Lower manufacturing costs compared to biologics
- Platform technology with multiple indication potential
- **Synergistic with current therapies:** Can combine with biologics or immunomodulators

5.3 Regulatory and Commercialization Strategy

Regulatory Pathway:

- 505(b)(2) NDA or Botanical Drug pathway (food-derived EVs = GRAS potential)
- Phase IIa: 50–80 patients, proof-of-concept (barrier repair biomarkers)
- Phase IIb/III: 200–400 patients, registration studies
- Target: FDA approval within 6–7 years post-Phase I completion

Commercialization:

- Licensing to mid-tier pharma (Takeda, Ferring, AbbVie) post-Phase IIa
- Deal structure: $10M–20M upfront, $80M–120M milestones, 8–12% royalties
- Platform extension: Crohn's disease, skin barrier diseases, aging-related conditions

6 Conclusion and Strategic Vision

6.1 Innovation Summary

Our plant extracellular vesicle-mediated therapeutic glycerophospholipid platform represents a fundamental paradigm shift in inflammatory bowel disease treatment, moving from symptom management to direct membrane repair and barrier restoration. This revolutionary approach addresses the root membrane pathology underlying IBD while being deliberately distinct from limitations and prior art challenges associated with existing therapeutic strategies.

Key Innovation Elements:

- First systematic approach to IBD treatment through quantitatively defined membrane composition modification
- Novel therapeutic glycerophospholipid compositions (BRM, RPM) optimized for intestinal barrier repair
- Engineered plant EV delivery system combining natural tropism with therapeutic enhancement
- Clear intellectual property position: distinct from all existing prodrug, polymeric carrier, and standard PC supplement prior art

Technical Feasibility: The platform leverages Dr. María Beatriz Herrera Sánchez's world-class expertise in extracellular vesicle therapeutics, established methodologies for plant EV isolation and modification, and well-characterized phospholipid biochemistry for membrane repair applications.

Commercial Viability: With a $27 billion IBD therapeutics market and growing recognition of membrane-based disease mechanisms, our platform addresses significant unmet medical needs while establishing a foundation technology for multiple therapeutic applications.

6.2 Long-term Vision and Impact

Transformative Therapeutic Approach:

Our platform has the potential to establish membrane therapeutics as a new treatment paradigm for inflammatory diseases, fundamentally changing how clinicians approach conditions characterized by barrier dysfunction and membrane pathology.

Platform Extension Opportunities:

- Expansion to other inflammatory bowel conditions and gastrointestinal disorders
- Application to skin barrier diseases (atopic dermatitis, psoriasis)
- Development of membrane-protective therapies for aging-related conditions
- Preventive applications for high-risk populations

Global Health Impact: By providing a safe, effective, and affordable therapeutic approach for IBD and related conditions, our platform could significantly improve quality of life for millions of patients worldwide while reducing healthcare system burden.

6.3 Next Steps and Immediate Actions

Immediate Priorities (Weeks 1–4):

- File provisional patent applications protecting core platform innovations
- Submit SBIR Phase I application to NIH/NIDDK
- Establish key laboratory collaborations for specialized expertise (lipidomics, organoid models)

Short-term Objectives (Months 1–6):

- Initiate proof-of-concept studies outlined in SBIR Specific Aims
- Develop strategic partnerships with food industry for EV sourcing
- Engage with regulatory consultants for clinical development planning

This innovative membrane therapeutics platform represents not just an improvement in IBD treatment, but a foundational technology that could revolutionize how we approach inflammatory diseases characterized by barrier dysfunction. Through the combination of Dr. Herrera Sánchez's expertise, novel technical approaches, and strong commercial potential, we are positioned to make a transformative impact on patient care while establishing a new paradigm in membrane-based therapeutics.